Video

Educated Patient® Lung Cancer Summit: March 6, 2021

Author(s):

CURE staff

View the full CURE Educated Patient Lung Cancer Summit on demand.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of doctor.
Image of Dr. Boffa.
Most patients in accredited hospitals had smoking discussions documented, showing key care opportunities and smoking’s impact on treatment outcomes.
Image of Dr. Reznick
There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.
Image of smiling doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image of woman with blonde hair.
Related Content
Younger patients with lung cancer are more likely to have mutations that allow for targeted therapies: © stock.adobe.com.
May 19th 2025

Younger Patients With Lung Cancer Often Have Targetable Biomarkers

Spencer Feldman
Younger patients with lung cancer are more likely to have mutations that allow for targeted therapies, which can lead to more personalized and effective treatment.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Illustration of lungs.
May 15th 2025

Ventana MET RxDx Assay Receives FDA Approval as Companion Diagnostic in NSCLC

Ryan Scott
The FDA approved the Ventana MET RxDx assay, making it the first companion diagnostic to aid in determining MET protein expression in non-squamous NSCLC.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
"FDA" text
May 14th 2025

FDA Approves Emrelis in Previously Treated, Advanced NSCLC

Ryan Scott
The U.S. FDA has approved treatment with Emrelis for adult patients with previously treated, advanced NSCLC with high c-Met protein overexpression.
From left: Carolyn M. Williams, CPCS, and Susan Rux, PH.D., D.N.P., RN, ACNS-BC, CENP, CNE, CPCC, FACHE, LNCC, NEA-BC, NPD-BC, OCN
May 12th 2025

Inspirational Leader Shines Her Light Outward to Others

Carolyn M. Williams, CPCS
Dr. Susan Rux, a respected nursing leader and researcher, empowers teams, mentors future leaders, and advances inclusive clinical research in kidney cancer.